New $25 million boost helps Synageva get down to business of good medicine
This article was originally published in Scrip
Synageva BioPharma CEO Sanj K Patel said he has always held to the philosophy that good medicine is good business. And with the new $25 million in private equity his firm's investors ponied up this week, they obviously believe privately held Synageva is on the right development path to bring that good medicine to the marketplace, with the potential to provide a solid return on their investment.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.